Evidence map›Paper›PMID 37627968›Full record

ReviewDiagnostics (Basel, Switzerland)2023

Screening and Management of Coronary Artery Disease in Kidney Transplant Candidates.

Giuseppe Vadalà, Chiara Alaimo, Giancarlo Buccheri, Luca Di Fazio, Leandro Di Caccamo, Vincenzo Sucato, Manlio Cipriani, Alfredo Ruggero Galassi

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Giuseppe VadalàDivision of Cardiology, University Hospital Paolo Giaccone, 90100 Palermo, Italy.ORCID 0000-0003-0869-4855
Chiara AlaimoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90100 Palermo, Italy.ORCID 0000-0003-1309-5419
Giancarlo BuccheriDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90100 Palermo, Italy.
Luca Di FazioDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90100 Palermo, Italy.ORCID 0000-0002-8066-5832
Leandro Di CaccamoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90100 Palermo, Italy.
Vincenzo SucatoDivision of Cardiology, University Hospital Paolo Giaccone, 90100 Palermo, Italy.
Manlio CiprianiInstitute of Transplant and Highly Specialized Therapies (ISMETT) of Palermo, 90100 Palermo, Italy.
Alfredo Ruggero GalassiDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90100 Palermo, Italy.
University of Palermo · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITIstituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione · IT

Funding

Managing Editor Diagnostics Mrs. Chaya Zeng (email agreements with Dr. Vadalà) Managing Editor Diagnostics Mrs. Chaya Zeng (email agreements)
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients and during the first year after transplantation. For these reasons, and due to the shortage of organs available for transplant, it is of utmost importance to identify patients with a good life expectancy after transplant and minimize the transplant peri-operative risk. Various conditions, such as severe pulmonary diseases, recent myocardial infarction or stroke, and severe aorto-iliac atherosclerosis, need to be ruled out before adding a patient to the transplant waiting list. The effectiveness of systematic coronary artery disease (CAD) treatment before kidney transplant is still debated, and there is no universal screening protocol, not to mention that a nontailored screening could lead to unnecessary invasive procedures and delay or exclude some patients from transplantation. Despite the different clinical guidelines on CAD screening in kidney transplant candidates that exist, up to today, there is no worldwide universal protocol. This review summarizes the key points of cardiovascular risk assessment in renal transplant candidates and faces the role of noninvasive cardiovascular imaging tools and the impact of coronary revascularization versus best medical therapy before kidney transplant on a patient's cardiovascular outcome.

Indexed as

coronary artery diseaseend-stage renal diseasekidney transplant

Identifiers

PMID37627968
PMCPMC10453389
OpenAlexW4386030098

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.